Holders — by stockHoldings — by fund
Monashee Investment Management LLC
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-06-30 · filed with the SEC up to 45 days after quarter end · CIK 0001627608
$59.6M
disclosed book value
23
positions
8.5%
largest position share
Positions, as of 2026-06-30
top 23 of 23 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | GOOGL 6.25 05/15/29 AALPHABET INC | 100,000 | $5.1M | 8.5% |
| 2 | GOOGL 6.25 05/15/29 BALPHABET INC | 100,000 | $5.0M | 8.4% |
| 3 | SLDBSOLID BIOSCIENCES INC | 500,000 | $5.0M | 8.4% |
| 4 | DLRDIGITAL RLTY TR INC | 25,000 | $4.5M | 7.5% |
| 5 | SYRESPYRE THERAPEUTICS INC | 50,000 | $4.4M | 7.5% |
| 6 | ADTADT INC DEL | 600,000 | $3.9M | 6.5% |
| 7 | TNGXTANGO THERAPEUTICS INC | 100,000 | $3.1M | 5.2% |
| 8 | CELC 0.25 08/01/32CELCUITY INC | 2.5M | $2.8M | 4.8% |
| 9 | SMCI 7 06/01/29SUPER MICRO COMPUTER INC | 50,000 | $2.6M | 4.4% |
| 10 | LEGNLEGEND BIOTECH CORP | 85,385 | $2.5M | 4.1% |
| 11 | GOOGLALPHABET INC | 6,000 | $2.1M | 3.6% |
| 12 | GOOGALPHABET INC | 6,000 | $2.1M | 3.6% |
| 13 | UNIQURE NV | 45,000 | $2.1M | 3.5% |
| 14 | INNIO NV | 47,650 | $1.9M | 3.2% |
| 15 | AKRACADIA RLTY TR | 85,385 | $1.8M | 3% |
| 16 | PTRNPATTERN GROUP INC | 64,039 | $1.6M | 2.7% |
| 17 | PCT 4.75 07/01/32PURECYCLE TECHNOLOGIES INC | 1.5M | $1.5M | 2.6% |
| 18 | MLTXMOONLAKE IMMUNOTHERAPEUTICS | 75,000 | $1.5M | 2.5% |
| 19 | WHKWHITEHAWK MINERALS CORP | 51,232 | $1.4M | 2.4% |
| 20 | TSHATAYSHA GENE THERAPIES INC | 200,000 | $1.4M | 2.3% |
| 21 | IMAIMAGENEBIO INC | 192,344 | $1.1M | 1.9% |
| 22 | NUVB 0.75 07/01/32NUVATION BIO INC | 1.0M | $1.1M | 1.8% |
| 23 | KARDKARDIGAN INC | 42,693 | $1.0M | 1.7% |
Source: SEC Form 13F-HR, reporting period 2026-06-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.